Resultados de procura - Beodeul Kang
- Mostrando 1 - 14 Resultados de 14
-
1
-
2
-
3
Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study por Beom Kyung Kim, Jaekyung Cheon, Hyeyeong Kim, Beodeul Kang, Yeonjung Ha, Do Young Kim, Seong Gyu Hwang, Young Eun Chon, Hong Jae Chon
Publicado 2022Artigo -
4
Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment por Young Eun Chon, Jaekyung Cheon, Hyeyeong Kim, Beodeul Kang, Yeonjung Ha, Do young Kim, Seong Gyu Hwang, Hong Jae Chon, Beom Kyung Kim
Publicado 2022Artigo -
5
-
6
Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma por Chan Kim, Hannah Yang, Il Hwan Kim, Beodeul Kang, Hyeyeong Kim, Hyunho Kim, Won Suk Lee, Sanghoon Jung, Ho Yeong Lim, Jaekyung Cheon, Hong Jae Chon
Publicado 2022Artigo -
7
Machine learning-based model to predict delirium in patients with advanced cancer treated with palliative care: a multicenter, patient-based registry cohort por Yu Jung Kim, Hayeon Lee, Ho Geol Woo, Si Won Lee, Moonki Hong, Eun Hee Jung, Shin Hye Yoo, Jinseok Lee, Dong Keon Yon, Beodeul Kang
Publicado 2024Artigo -
8
Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer por Yu Seong Lee, Won Suk Lee, Chang Woo Kim, Seung Joon Lee, Hannah Yang, So Jung Kong, John Ning, Kyung-Mee Yang, Beodeul Kang, Woo Ram Kim, Hong Jae Chon, Chan Kim
Publicado 2020Artigo -
9
STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer por Seung Joon Lee, Hannah Yang, Woo Ram Kim, Yu Seong Lee, Won Suk Lee, So Jung Kong, Hye Jin Lee, Jeong Hun Kim, Jaekyung Cheon, Beodeul Kang, Hong Jae Chon, Chan Kim
Publicado 2021Artigo -
10
High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma por Hannah Yang, Beodeul Kang, Yeonjung Ha, Sung Hwan Lee, Il Hwan Kim, Hyeyeong Kim, Won Suk Lee, Gwangil Kim, Sanghoon Jung, Sun Young Rha, Vincent E. Gaillard, Jaekyung Cheon, Chan Kim, Hong Jae Chon
Publicado 2023Artigo -
11
Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study por Young Eun Chon, Dong Yun Kim, Mina Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Yeonjung Ha, Joo Ho Lee, Kwan Sik Lee, Beodeul Kang, Jung Sun Kim, Hong Jae Chon, Do Young Kim
Publicado 2024Artigo -
12
A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer por Choong‐kun Lee, Sun Young Rha, Hyo Song Kim, Minkyu Jung, Beodeul Kang, Jingmin Che, Woo Sun Kwon, Sejung Park, Woo Kyun Bae, Dong‐Hoe Koo, Su‐Jin Shin, Hyunki Kim, Hei‐Cheul Jeung, Dae Young Zang, Sang Kil Lee, Chung Mo Nam, Hyun Cheol Chung
Publicado 2022Artigo -
13
Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial por Hyung‐Don Kim, Seyoung Jung, Ho Yeong Lim, Baek‐Yeol Ryoo, Min‐Hee Ryu, Samuel Chuah, Hong Jae Chon, Beodeul Kang, Jung Yong Hong, Han Chu Lee, Deok‐Bog Moon, Ki‐Hun Kim, Tae Won Kim, David Tai, Valerie Chew, Jeong Seok Lee, Richard S. Finn, June‐Young Koh, Changhoon Yoo
Publicado 2024Artigo -
14
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis por Margherita Rimini, Lorenza Rimassa, Kazuomi Ueshima, Valentina Burgio, S. Shigeo, Toshifumi Tada, Goki Suda, Chi‐Hyeon Yoo, Jaekyung Cheon, David J. Pinato, Sara Lonardi, Mario Scartozzi, Massimo Iavarone, G.G. Di Costanzo, Fabio Marra, Caterina Soldà, Emiliano Tamburini, Fabio Piscaglia, Gianluca Masi, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Tiziana Pressiani, Naoshi Nishida, Hideki Iwamoto, Naoya Sakamoto, Baek‐Yeol Ryoo, Hong Jae Chon, F. Claudia, Takashi Niizeki, Takuya Sho, Beodeul Kang, Antonio D’Alessio, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiro Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, T. Nishimur, Takeshi Hatanaka, Satoru Kakizaki, Naohiko Shimada, Kazuhito Kawata, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, T. Arai, Michitaka Imai, Atsushi Naganuma, Yuichiro Koizumi, Shinichiro Nakamura, Kouji Joko, Hiroko Iijima, Yoichi Hiasa, Federica Pedica, Francesco De Cobelli, Francesca Ratti, Luca Aldrighetti, Masatoshi Kudo, Stefano Cascinu, Andrea Casadei‐Gardini
Publicado 2022Artigo
Ferramentas de procura:
Materias Relacionadas
Medicine
Cancer
Internal medicine
Oncology
Immunotherapy
Atezolizumab
Chemotherapy
Hepatocellular carcinoma
Nivolumab
Bevacizumab
Gastroenterology
Adverse effect
Cancer research
Cohort
Confidence interval
Hazard ratio
Immunology
Lenvatinib
Sorafenib
Biology
Clinical endpoint
Clinical trial
Cohort study
Colorectal cancer
Immune system
Pembrolizumab
Surgical oncology
Aerospace engineering
Alkaline phosphatase
Anatomy